Article Sidebar

pdf
Date Published: 11/04/2025
Abstract Views: 39
Views pdf: 18
DOI: https://doi.org/10.51298/vmj.v548i2.13415
Issue
Vol. 548 No. 2 (2025)
Section
Các bài báo
How to Cite
Nguyễn, Đức L., & Hoàng, T. T. L. (2025). OVERALL SURVIVAL OF CHILDREN WITH MEDULLOBLASTOMA POST SURGERY, ADJUVANT CHEMOTHERAPY AND RADIOTHERAPY. Vietnam Medical Journal, 548(2). https://doi.org/10.51298/vmj.v548i2.13415

OVERALL SURVIVAL OF CHILDREN WITH MEDULLOBLASTOMA POST SURGERY, ADJUVANT CHEMOTHERAPY AND RADIOTHERAPY

Đức Liên Nguyễn, Thị Thùy Linh Hoàng

Main Article Content

Abstract

Objective: To evaluate the overall survival and disease-free survival of children with medulloblastoma treated with surgery, adjuvant chemotherapy and radiotherapy at K Hospital. Methods: Medulloblastoma patients underwent multimodality treatment at K Hospital from January 2019 to December 2023. A retrospective desciptive study. Patients were re-examined and evaluated the treatment results by clinical examination and MRI scan. Results: A total of 45 patients, mean age was 9.09 years. The 5-year overall survival (OS) and disease-free survival (PFS) rates were 54.3% and 62.0%, respectively. The OS of high-risk medulloblastoma group was 34.3 months, the intermediate-risk group was 64.7 months, the difference was statistically significant with p=0.001. The overall survival in the total tumor resection group was 53.9 months, the near-total tumor resection group (51 months) and the partial tumor resection group (16.6 months), the difference was statistically significant with p=0.002. The OS in the group without spinal cord metastasis was 61.3 months, the group with spinal cord metastasis was 19.4 months, the difference was statistically significant with p<0.01. There was no statistically significant difference in survival time according to age and pathology (p>0.05). Conclusion: The 5-years overall survival of multimodality treatment for medulloblastoma were 54.3% and 62.0%, respectively.

Article Details

Keywords

medulloblastoma, overall survival, chemoradiotherapy.

References

Smoll NR, Drummond KJ (2012). The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci Off J Neurosurg Soc Australas, 19(11):1541-1544.
2. Price M, Neff C, Nagarajan N, et al (2024). CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016–2020. Neuro-Oncol, 26(Supplement_3):iii1-iii53.
3. Louis DN, Perry A, Wesseling P, et al (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol, 23(8):1231-1251.
4. Taylor MD, Northcott PA, Korshunov A, et al (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (Berl), 123(4):465-472.
5. Dhall G (2009). Medulloblastoma. J Child Neurol, 24(11):1418-1430.
6. Kumar R, Achari G, Banerjee D, Chhabra D (2001). Uncommon presentation of medulloblastoma. Child’s Nerv Syst, 17(9):538-542.
7. Trần Văn Học, Nguyễn Văn Thắng, Nguyễn Thanh Liêm (2012). Kết quả điều trị u nguyên tủy bào ở trẻ em tại bệnh viện Nhi trung ương. Tạp chí nghiên cứu Y học, 80(3):53-57.
8. David KM, Casey AT, Hayward RD, Harkness WF, Phipps K, Wade AM (1997). Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J Neurosurg, 86(1):13-21.
9. M G Belza (1991). Medulloblastoma: freedom from relapse longer than 8 years - a therapeutic cure. J Neurosurg, 75(4):575-82.
10. Adamski J, Ramaswamy V, Huang A, Bouffet E (2014). Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors. F1000Prime Rep. 2014;6:56.